# US 2021/0060086 A1 · Combination therapy for treating or preventing cancer

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0060086 A1
- Document ID: US20210060086A1
- Status: Published application
- Kind: A1
- Application number: 16/931,104
- Filed: 2020-07-16
- Published: 2021-03-04
- Earliest claimed: 2018-01-19
- Assignees: 4D Pharma Research Limited
- Applicants: 4D Pharma Research Limited
- Inventors: Alexander STEVENSON
- Web page: https://patentgrep.com/patent/US20210060086A1

## CPC

- A61K 35/74: Bacteria (therapeutic use of a bacterial protein A61K38/00)
- A61K 39/395: Antibodies (agglutinins A61K38/36 {; as drug carriers A61K47/50}); Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61P 35/00: Antineoplastic agents
- C07K 16/2818: {against CD28 or CD152}
- C07K 16/3084: {against tumour-associated gangliosides}
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 2039/505: {comprising antibodies}
- A61K 2039/52: {Bacterial cells; Fungal cells; Protozoal cells}
- A61K 2039/57: {characterised by the type of response, e.g. Th1, Th2}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The invention provides a combination therapy comprising a bacterial strain for treating or preventing cancer.

## Claims

### Claim at position 1

-24. (canceled)

### Claim 25

A method of treating cancer in a subject in need thereof, comprising
administering to said subject (i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and (ii) a second pharmaceutical composition that comprises a checkpoint inhibitor, wherein said checkpoint inhibitor is an anti-ganglioside GD3 antibody or a ganglioside GD3 binding fragment thereof,
whether said first pharmaceutical composition is administered to said subject by oral administration and said second pharmaceutical composition is administered to said subject by parenteral administration, and
wherein said administering is effective to treat cancer in said subject.

### Claim 26 (depends on 25)

The method of claim 25, wherein said second pharmaceutical composition is administered to said subject by subcutaneous or intravenous administration.

### Claim 27 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is administered to said subject daily or every other day.

### Claim 28 (depends on 25)

The method of claim 25, wherein said second pharmaceutical composition is administered to said subject twice a week, once every 7 days, once every 14 days, once every 21 days, or once every 28 days.

### Claim 29 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is administered to said subject daily and said second pharmaceutical composition is administered to said subject every 14 days.

### Claim 30 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is administered to said subject daily and said second pharmaceutical composition is administered to said subject every 21 days.

### Claim 31 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is administered to said subject daily and said second pharmaceutical composition is administered to said subject every 28 days.

### Claim 32 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is administered to said subject prior to first administration of said second pharmaceutical composition.

### Claim 33 (depends on 32)

The method of claim 32, wherein said first pharmaceutical composition is administered to said subject for at least 7, 14, 21, or 28 days prior to said first administration of said second pharmaceutical composition.

### Claim 34 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is administered to said subject at least partially in parallel to administration of said second pharmaceutical composition.

### Claim 35 (depends on 25)

The method of claim 25, wherein said cancer is solid tumor cancer.

### Claim 36 (depends on 25)

The method of claim 25, wherein said cancer is any one selected from the group consisting of lung cancer, breast cancer, kidney cancer, liver cancer, lymphoma, hepatoma, neuroendocrine cancer, melanoma, bladder cancer, and colon cancer.

### Claim 37 (depends on 36)

The method of claim 36, wherein said cancer is non-small cell lung cancer.

### Claim 38 (depends on 25)

The method of claim 25, wherein said subject is non-responsive or partially responsive to administering said second pharmaceutical composition alone, as compared to said administering.

### Claim 39 (depends on 38)

The method of claim 38, wherein said subject has not been administered with an anti-cancer agent or therapy for treating said cancer prior to said administering.

### Claim 40 (depends on 25)

The method of claim 25, wherein said subject is intolerance to a chemotherapy treatment.

### Claim 41 (depends on 25)

The method of claim 25, wherein said administering is more effective to treat cancer as compared to administering said second pharmaceutical composition alone or as compared to administering said first pharmaceutical composition alone.

### Claim 42 (depends on 25)

The method of claim 25, wherein said bacterial strain is dried.

### Claim 43 (depends on 25)

The method of claim 25, wherein said therapeutically effective amount of said bacteria strain comprises from about 1×103 to about 1×1011 colony forming units (CFU)/g of said bacteria strain with respect to the total weight of said first pharmaceutical composition.

### Claim 44 (depends on 25)

The method of claim 25, wherein said bacteria strain is capable of at least partially colonizing an intestine of said subject.

### Claim 45 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition is formulated for delivery to an intestine of said subject.

### Claim 46 (depends on 25)

The method of claim 25, wherein said bacteria strain comprises a 16S rRNA gene that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62.

### Claim 47 (depends on 25)

The method of claim 25, wherein said bacteria strain comprises a 16S rRNA gene sequence that is the polynucleotide sequence of SEQ ID NO: 2.

### Claim 48 (depends on 25)

The method of claim 25, wherein said bacterial strain is of species Enterococcus gallinarum.

### Claim 49 (depends on 25)

The method of claim 25, wherein said bacterial strain is the strain deposited under accession number NCIMB 42488.

### Claim 50 (depends on 25)

The method of claim 25, wherein said anti-ganglioside GD3 antibody or said ganglioside GD3 binding fragment thereof is conjugated as an antibody-drug conjugate (ADC).

### Claim 51 (depends on 50)

The method of claim 50, wherein said antibody-drug conjugate (ADC) is PF-06688992.

### Claim 52 (depends on 25)

The method of claim 25, wherein said first pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, carriers, or diluents.

### Claim 53 (depends on 25)

The method of claim 25, wherein said second pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, carriers, or diluents.

### Claim 54 (depends on 25)

The method of claim 25, further comprising administering a third pharmaceutical composition that comprises lipopolysaccharide.

### Claim 55 (depends on 25)

The method of claim 25, wherein said administering increases the level of IFN-γ in the tumor microenvironment, increases the levels of IL-6 or IL-23 in the blood, or induces localization of CD8a positive cells in the ileum.

### Claim 56

A kit for treating cancer in a subject in need thereof, comprising
(i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and
(ii) a second pharmaceutical composition that comprises a checkpoint inhibitor, wherein said checkpoint inhibitor is an anti-ganglioside GD3 antibody or a ganglioside GD3 binding fragment thereof.

### Claim 57

A method of treating cancer in a subject in need thereof, comprising
administering to said subject (i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and (ii) a second pharmaceutical composition that comprises a checkpoint inhibitor selected from the group consisting of: Nivolumab, BGB-A317, cemiplimab, PDR001, camrelizumab, BCD-100, IBI308, AGEN2034, INCSHR1210, MEDI0680, JS001/PD1, CC-90006, BI 754091, JNJ-63723283, PF-06801591, GLS-010, AB122, Sym021, MGA012, LZM009, genolimzumab, AK105, and TSR-042,
whether said first pharmaceutical composition is administered to said subject by oral administration and said second pharmaceutical composition is administered to said subject by parenteral administration, and
wherein said administering is effective to treat cancer in said subject.

### Claim 58 (depends on 57)

The method of claim 57, wherein said second pharmaceutical composition is administered to said subject by subcutaneous or intravenous administration.

### Claim 59 (depends on 58)

The method of claim 58, wherein said second pharmaceutical composition is administered to said subject by intravenous infusion.

### Claim 60 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is administered to said subject daily or every other day.

### Claim 61 (depends on 57)

The method of claim 57, wherein said second pharmaceutical composition is administered to said subject twice a week, once every 7 days, once every 14 days, once every 21 days, or once every 28 days.

### Claim 62 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is administered to said subject daily and said second pharmaceutical composition is administered to said subject every 14 days.

### Claim 63 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is administered to said subject daily and said second pharmaceutical composition is administered to said subject every 21 days.

### Claim 64 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is administered to said subject daily and said second pharmaceutical composition is administered to said subject every 28 days.

### Claim 65 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is administered to said subject prior to first administration of said second pharmaceutical composition.

### Claim 66 (depends on 65)

The method of claim 65, wherein said first pharmaceutical composition is administered to said subject for at least 7, 14, 21, or 28 days prior to said first administration of said second pharmaceutical composition.

### Claim 67 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is administered to said subject at least partially in parallel to administration of said second pharmaceutical composition.

### Claim 68 (depends on 57)

The method of claim 57, wherein said cancer is solid tumor cancer.

### Claim 69 (depends on 57)

The method of claim 57, wherein said cancer is any one selected from the group consisting of lung cancer, breast cancer, kidney cancer, liver cancer, lymphoma, hepatoma, neuroendocrine cancer, melanoma, bladder cancer, and colon cancer.

### Claim 70 (depends on 69)

The method of claim 69, wherein said cancer is non-small cell lung cancer.

### Claim 71 (depends on 57)

The method of claim 57, wherein said subject is non-responsive or partially responsive to administering said second pharmaceutical composition alone, as compared to said administering.

### Claim 72 (depends on 71)

The method of claim 71, wherein said subject has not been administered with an anticancer agent or therapy for treating said cancer prior to said administering.

### Claim 73 (depends on 57)

The method of claim 57, wherein said subject is intolerance to a chemotherapy treatment.

### Claim 74 (depends on 57)

The method of claim 57, wherein said administering is more effective to treat cancer as compared to administering said second pharmaceutical composition alone or as compared to administering said first pharmaceutical composition alone.

### Claim 75 (depends on 57)

The method of claim 57, wherein said bacterial strain is dried.

### Claim 76 (depends on 57)

The method of claim 57, wherein said therapeutically effective amount of said bacteria strain comprises from about 1×103 to about 1×1011 colony forming units (CFU)/g of said bacteria strain with respect to the total weight of said first pharmaceutical composition.

### Claim 77 (depends on 57)

The method of claim 57, wherein said bacteria strain is capable of at least partially colonizing an intestine of said subject.

### Claim 78 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition is formulated for delivery to an intestine of said subject.

### Claim 79 (depends on 57)

The method of claim 57, wherein said bacteria strain comprises a 16S rRNA gene that has at least 99% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62.

### Claim 80 (depends on 57)

The method of claim 57, wherein said bacteria strain comprises a 16S rRNA gene sequence that is the polynucleotide sequence of SEQ ID NO: 2.

### Claim 81 (depends on 57)

The method of claim 57, wherein said bacterial strain is of species Enterococcus gallinarum.

### Claim 82 (depends on 57)

The method of claim 57, wherein said bacterial strain is the strain deposited under accession number NCIMB 42488.

### Claim 83 (depends on 57)

The method of claim 57, wherein said first pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, carriers, or diluents.

### Claim 84 (depends on 57)

The method of claim 57, wherein said second pharmaceutical composition further comprises one or more pharmaceutically acceptable excipients, carriers, or diluents.

### Claim 85 (depends on 57)

The method of claim 57, further comprising administering a third pharmaceutical composition that comprises lipopolysaccharide.

### Claim 86 (depends on 57)

The method of claim 57, wherein said administering increases the level of IFN-γ in the tumor microenvironment, increases the levels of IL-6 or IL-23 in the blood, or induces localization of CD8α positive cells in the ileum.

### Claim 87

A kit for treating cancer in a subject in need thereof, comprising
(i) a first pharmaceutical composition that comprises a therapeutically effective amount of a bacteria strain of the genus Enterococcus, wherein said bacteria strain comprises a 16S rRNA gene that has at least 95% sequence identity to the polynucleotide sequence of SEQ ID NO: 2, as determined by a Smith-Waterman homology search algorithm using an affine gap search with a gap open penalty of 12 and a gap extension penalty of 2, and a BLOSUM matrix of 62, and
(ii) a second pharmaceutical composition that comprises a checkpoint inhibitor selected from the group consisting of: Nivolumab, BGB-A317, cemiplimab, PDR001, camrelizumab, BCD-100, IBI308, AGEN2034, INCSHR1210, MEDI0680, JS001/PD1, CC-90006, BI 754091, JNJ-63723283, PF-06801591, GLS-010, AB122, Sym021, MGA012, LZM009, genolimzumab, AK105, and TSR-042.
